Search for: "TEVA PHARMACEUTICALS v. ELI LILLY AND COMPANY "
Results 61 - 80
of 84
Sorted by Relevance
|
Sort by Date
15 Jun 2011, 4:56 am
(Patent Docs) Strattera (Atomoxetine)- US: Patent infringement complaint filed in response to Para IV certification: Eli Lilly & Co. v. [read post]
18 Jul 2014, 11:55 am
Teva Pharmaceuticals USA, Inc., 2010 WL 2640170, at *2 (W.D. [read post]
13 May 2010, 4:58 pm
(Patent Docs) Evista (Raloxifene) – US: Patent infringement complaint following a Paragraph IV certification: Eli Lilly & Company v. [read post]
2 Jun 2011, 12:46 pm
Ortho Pharmaceutical Corp., 661 N.E.2d 352, 354 (Ill. 1996); Frye v. [read post]
5 Jul 2013, 5:00 am
Eli Lilly & Co., 420 A.2d 1305, 1320 (N.J. [read post]
18 Feb 2020, 4:00 am
Pfizer Canada ULC, 2020 FC 1, at para. 42. [3] See Sections 27(3)(b) and 28.3 of the Patent Act, RSC 1985, c P-4 [4] Burton Parsons Chemicals, Inc v Hewlett-Packard (Canada) Ltd, [1976] 1 SCR 555 at 563 [5] Apotex Inc v Sanofi-Synthelabo Canada Inc, 2008 SCC 61 at paragraph 37, [2008] 3 SCR 265; see also Bell Helicopter Textron Canada Limitée v Eurocopter, société par actions simplifiée, 2013 FCA 219 at paragraph 65; Mylan… [read post]
21 Oct 2014, 9:03 am
In Bristol-Myers Squibb Company v. [read post]
24 Feb 2011, 1:49 pm
Teva Pharmaceuticals, 726 F. [read post]
15 Mar 2008, 7:00 am
India: Gene silencing: (Spicy IP), India: US Patent reform implications for Indian Pharma: (Spicy IP), India: Generic pharmaceutical industry in the spotlight: (International Law Office), India: Supreme Court refuses to stay a Gujarat High Court decision restraining Ranbaxy from airing its controversial ads directed against Paras Pharma's 'Moov' brand: (Spicy IP),India: Patents on ARV drugs could increase costs: (Generic Pharmaceuticals & IP),US: Survey… [read post]
8 Feb 2008, 7:00 pm
– Facebook’s contractual rights to users’ photos problematic: (Spicy IP)PharmaEuropean Commission probes pharmaceutical sector: (Philip Brooks),WHO Board sets course on IP, avian flu, tighter publication policy: (Intellectual Property Watch),India: The Competition Act, patents and over hyped drugs: (Part I - Spicy IP), (Part II – Spicy IP), (Part III – Spicy IP),Ignoring not the solution … [read post]
23 Dec 2007, 8:00 pm
You can separately subscribe to the IP Thinktank Global week in Review at [feeds.feedburner.com]GlobalEvents in Bali heap further pressure on all IP owners: (IAM),Velcro defies generic claim in domain name battle: (OUT-LAW),ICANN forms group to hasten non-English domain names: (IP Justice)WTO members continue debate on geographical indications register: (Intellectual Property Watch),Creative Commons launches CCo and CC programs: (World IP Day),Green IP Strategy - risks… [read post]
22 Jan 2009, 2:06 am
Thus the plaintiff could proceed against the non-manufacturer pioneer company, even though the plaintiff's claims against the actual manufacturers were properly dismissed on warning causation grounds. [read post]
18 Jul 2008, 8:34 am
: (Patent Circle), Tanzania to conduct study on impact of counterfeit medicines: (Afro-IP), US: New rules on generic biological medicines under US Congressional debate: (Intellectual Property Watch), Pharma & Biotech - Products Acular (Ketorolac) – US: CAFC rules against Apotex reverse doctrine of equivalents: Roche Palo Alto & Allergan, Inc v Apotex: (Patent Circle), Carbatrol (Carbamazapine) – US: Federal judge allows Corepharma to seek DJ that its… [read post]
2 Aug 2008, 12:54 am
: (Holman’s Biotech IP Blog), Daiichi’s open offer for 20% in Ranbaxy awaits Sebi nod: (GenericsWeb), Australia/India: Strides shows thumbs up for Indian generic industry acquiring controlling interest in Ascent: (Spicy IP), Europe: Significant date ahead for EU Paediatric Regulation: (SPC Blog), India: Grave diggers, ‘immoral’ patent and the National Biotech Regulatory Authority: (Spicy IP), UK: Monster trade mark infringement case: court reveals its thinking… [read post]
7 Mar 2008, 2:00 am
: (IPBiz), US: Proposals for the approval of generic biologics under consideration: (Pharmacapsules@Gowlings), US: A paradigm shift in obviousness for pharma, biotech: (IP Law360), US: USPTO’s Bruce Kisliuk addresses ACI Pharma/biotech patent claim drafting and prosecution conference: (Patent Docs), US: New bill to provide biotech companies Sarbanes-Oxley relief: (California Biotech Law Blog), US: Biotech and pharma companies spent millions on lobbying… [read post]
5 Jul 2008, 11:05 am
: (IP tango), China: Pfizer loses trade mark action against Jaingsu Lianhuan Pharmaceutical Co over 3D mark: (Rouse & Co International), India: More patents for new forms issued to generics: (Patent Circle), India: Gauri Kamath on drug ‘differential pricing’ in India: (Spicy IP), Mexico: Revised health supplies regulations promise changes for generics: (International Law Office), US: World drug pricing crisis: Congressmen criticise US Trade Representative over… [read post]
11 Jul 2008, 4:30 am
Part I – Spicy IP), India: Discussion of grant of Indian patents to Cipla for Fosamax derivative and Nexium derivative: (Spicy IP), India: Draft National Biotechnology Regulatory Authority Bill: (Spicy IP), Ivory Coast: Ivorians increasingly choose fake medicines on price: (Afro-IP), Mexico: New Mexican medicaments approvals regime: an early report: (IP tango), UK: Leave to appeal refused in trade mark infringement proceedings between Eli Lilly and 8PM Chemist concerning… [read post]
9 Aug 2008, 1:50 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: The end of William Patry’s blog: (Patry Copyright Blog), (Excess Copyright), (Patently-O), (Chicago IP Litigation Blog), (Michael Geist), (The Fire of Genius), (Techdirt), (Patry Copyright Blog), Kitchin J clarifies scope of biotech patents, in particular gene sequence patents: Eli Lilly & Co v Human… [read post]
22 Feb 2008, 6:00 pm
: (GenericsWeb), EU: Pharmaceutical sector enquiry regarding possible misuse of IP rights: (GenericsWeb), India: Indian government seeks to be a leader in deep sea bed mining to provide competitive edge for pharmaceutical companies in the development of new drugs: (Spicy IP),India : Medical Devices Regulation Bill formulated: (Spicy IP),India : Pharma gets bigger - Novo Nordisk and Merck & Co expansion plans: (Spicy IP),India : US patent reform and the Indian… [read post]
17 Mar 2020, 1:32 pm
One lot of Glucagon Emergency Kits have been recalled by Eli Lilly and Company due to a potentially dangerous loss of potency. [read post]
